Cerus (CERS) Cash from Financing Activities (2010 - 2026)
Cerus (CERS) posted Cash from Financing Activities of -$20.0 million for Q2 2026, down 1781.12% sequentially from $1.2 million in Q1 2026, and down 15434.11% YoY from N/an in Q2 2025.
Cerus (CERS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Cerus has reported Cash from Financing Activities for 17 years, with the latest figure at -$20.0 million in Q2 2026.
- Quarterly Cash from Financing Activities fell 15434.11% year-over-year to -$20.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$19.6 million (down 1218.88% YoY) and the FY2025 annual result came in at $231000.0, down 95.35% from the prior year.
- Cash from Financing Activities slipped to -$20.0 million in Q2 2026 per CERS's latest filing, from $1.2 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $7.6 million in Q3 2023 and troughed at -$20.0 million in Q2 2026.
- A 5-year average of $67388.9 and a median of $601500.0 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities soared 601.29% in 2023, then sank 15434.11% in 2026.
- Over 5 years, Cash from Financing Activities stood at $457000.0 in 2022, then surged by 158.86% to $1.2 million in 2023, then tumbled by 36.94% to $746000.0 in 2024, then plunged by 238.2% to -$1.0 million in 2025, then sank by 1843.65% to -$20.0 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$20.0 million, $1.2 million, and -$1.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Cerus | 560.58 Mn | 504.32 Mn | 29.53 Mn | -20.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.04 Mn |
| Jun 30, 2026 | -20.04 Mn |
| Mar 31, 2026 | 1.19 Mn |
| Mar 31, 2026 | 1.19 Mn |
| Dec 31, 2025 | -1.03 Mn |
| Dec 31, 2025 | -1.03 Mn |
| Sep 30, 2025 | 320,000.00 |
| Sep 30, 2025 | 320,000.00 |
| Jun 30, 2025 | -129,000.00 |
| Jun 30, 2025 | -129,000.00 |
| Mar 31, 2025 | 1.07 Mn |
| Mar 31, 2025 | 1.07 Mn |
| Dec 31, 2024 | 746,000.00 |
| Dec 31, 2024 | 746,000.00 |
| Sep 30, 2024 | 60,000.00 |
| Sep 30, 2024 | 60,000.00 |
| Jun 30, 2024 | -1.40 Mn |
| Jun 30, 2024 | -1.40 Mn |
| Mar 31, 2024 | 5.56 Mn |
| Mar 31, 2024 | 5.56 Mn |